Get the Stockscreener App
10.81
0.01%
0.013
Urogen Pharma Ltd stock is traded at $10.81, with a volume of 41,303.
It is up +0.01% in the last 24 hours and up +2.67% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$10.82
Open:
$10.78
24h Volume:
41,303
Relative Volume:
0.11
Market Cap:
$459.55M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-2.9447
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
+6.20%
1M Performance:
+2.67%
6M Performance:
-17.52%
1Y Performance:
-38.06%
1-Day Range:
$10.72
$11.14
1-Week Range:
$9.11
$11.73
52-Week Range:
$9.03
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
10.81 | 459.55M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.49 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.02 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.08 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.73 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.72 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Urogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch target - MSN
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strat - GuruFocus.com
UroGen Pharma (NASDAQ:URGN) Price Target Cut to $55.00 by Analysts at HC Wainwright - Defense World
UroGen Pharma stock target cut to $55 at H.C. Wainwright By Investing.com - Investing.com Australia
UroGen Pharma stock target cut to $36 at Raymond James By Investing.com - Investing.com Australia
UroGen Pharma stock target cut to $55 at H.C. Wainwright - Investing.com India
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call Transcript - Insider Monkey
UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - Defense World
UroGen Pharma Reports Strong Pipeline Progress and Revenue Growth - TipRanks
UroGen Pharma Ltd. SEC 10-K Report - TradingView
Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results By Investing.com - Investing.com South Africa
UroGen Pharma shares fall as Q4 results miss estimates By Investing.com - Investing.com South Africa
UroGen Pharma shares fall as Q4 results miss estimates - Investing.com
Earnings call transcript: UroGen Pharma Q4 2024 reports mixed results - Investing.com India
Urogen Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Urogen Pharma reports wider-than-expected fourth-quarter loss -March 10, 2025 at 10:56 am EDT - Marketscreener.com
Oppenheimer & Co. Inc. Acquires Shares of 11,875 UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Australia
UroGen Pharma Posts Wider Loss In Q4Quick Facts - Nasdaq
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 - Joplin Globe
Rhumbline Advisers Has $546,000 Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bluefield Daily Telegraph
UroGen Strengthens Jelmyto Commercialization: Key Details on New Team RSU Package - StockTitan
UroGen Pharma Ltd. to Host Earnings Call - ACCESS Newswire
UroGen Pharma (URGN) to Release Earnings on Thursday - Defense World
BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight - GlobeNewswire Inc.
How to Take Advantage of moves in (URGN) - Stock Traders Daily
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 - StockTitan
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from HC Wainwright - Defense World
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? - Yahoo Finance UK
UroGen stock holds Buy rating, $64 target from H.C. Wainwright By Investing.com - Investing.com South Africa
UroGen stock holds Buy rating, $64 target from H.C. Wainwright - Investing.com
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference - BioSpace
Can UroGen's Next Move Transform Urothelial Cancer Treatment? Key Insights Coming at TD Cowen - StockTitan
UroGen acquires IconOVir’s oncolytic virus assets - Yahoo Finance
UroGen Pharma (NASDAQ:URGN) Coverage Initiated at LADENBURG THALM/SH SH - Defense World
UroGen Plots Expansion, Brings In A New Asset - Insights
Low-Gade Upper Tract Urothelial Cancer Market on Track for Major - openPR
UroGen acquires oncolytic virus, expands cancer treatment options By Investing.com - Investing.com Nigeria
UroGen Pharma Acquires Oncolytic Virus From IconOVir Bio -February 20, 2025 at 10:58 am EST - Marketscreener.com
UroGen stock in focus after IconOVir deal (URGN:NASDAQ) - Seeking Alpha
UroGen acquires oncolytic virus, expands cancer treatment options - Investing.com India
UroGen Pharma Expansion Of Oncology Pipeline Portfolio Through Acquisition Of Assets Relating To Oncolytic Virus Icvb-1042 From Iconovir Bio - Marketscreener.com
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations - Business Wire
Where are the Opportunities in (URGN) - Stock Traders Daily
UroGen Pharma’s (URGN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World
UroGen Announces Results from Subgroup Analyses of the Pivotal E - WICZ
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 - Business Wire
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Urogen Pharma Ltd Stock (URGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Jason Drew | General Counsel |
Jan 31 '25 |
Sale |
11.14 |
7,379 |
82,202 |
26,468 |
| Schoenberg Mark | Chief Medical Officer |
Sep 09 '24 |
Sale |
13.08 |
859 |
11,236 |
145,091 |
| Smith Jason Drew | General Counsel |
Sep 09 '24 |
Sale |
13.08 |
1,521 |
19,895 |
25,226 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):